U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07881887) titled 'A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes' on Oct. 13.
Brief Summary: The main purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight with or without Type 2 Diabetes. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration.
Participation in the study will last between approximately 53 to 89 weeks. For each participant (excluding those in Part B), the study will include between 5 and 7 stays in the Clinical R...